Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma

Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma

Lung cancer is the leading cause of cancer-related death in the United States. Here, we evaluated the potential clinical utility of soluble human epidermal growth factor receptor 2 (sHER2) for the risk assessment, screening, and diagnosis of non-small cell lung cancer (NSCLC) using an unmatched case...

Full description

Bibliographic Details
Main Authors:	Andre T. Baron, Nita J. Maihle, Ping Yang, Adam J. Branscum, Yuxia Wang, Marites C. Buenafe, Kimberly D. Kimbler, Tammy M. Greenwood, Abby L. Cosentino-Boehm, Jacqueline M. Lafky
Format:	Article
Language:	English
Published:	MDPI AG 2013-01-01
Series:	Diagnostics
Subjects:	soluble human epidermal growth factor receptor 2 (sHER2) non-small cell lung cancer adenocarcinoma squamous cell carcinoma (SCC) risk assessment screening early detection diagnosis
Online Access:	http://www.mdpi.com/2075-4418/3/1/13

Similar Items

Dysregulation of circulating sTie2 and sHER2 in HIV-infected women with preeclampsia
by: Mduduzi Mazibuko, et al.
Published: (2019-04-01)

A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
by: Fnu Amisha, et al.
Published: (2023-05-01)

Breast Carcinoma; Human Epidermal Growth Factor Receptor-2 (HER-2) and Grading Correlation
by: Seyed Abbas Mirmalek, et al.
Published: (2015-08-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)

Zonasi Konservasi untuk Siapa? Pengaturan Perairan Laut Taman Nasional Bali Barat
by: Amir Mahmud, et al.
Published: (2016-09-01)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
by: Lisandra Negrón-Vega, et al.
Published: (2022-09-01)

Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress
by: Hendrik Setia Budi, et al.
Published: (2022-01-01)

Inetetamab in combination with rapamycin and chemotherapy for trastuzumab‐treated metastatic human epidermal growth factor receptor 2‐positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway
by: Aijuan Wang, et al.
Published: (2023-09-01)

Evaluation of Human Epidermal Growth Factor Receptor-2 in Iraqi Women with Breast Cancer
by: Hiba Hadi Rashid, et al.
Published: (2019-06-01)

Evaluation of Human Epidermal Growth Factor Receptor-2 in Iraqi Women with Breast Cancer
by: Hiba Hadi Rashid, et al.
Published: (2019-06-01)

Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
by: Guochun Zhang, et al.
Published: (2022-04-01)

Dendritic epidermal T cells secreting exosomes promote the proliferation of epidermal stem cells to enhance wound re-epithelialization
by: Mian Liu, et al.
Published: (2022-03-01)

Gallbladder Adenocarcinoma, Potential Target for Anti-Her-2 Therapy
by: Ghazi Zafar, et al.
Published: (2020-08-01)

HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer
by: Ulrika Pellas, et al.
Published: (2023-07-01)

Creeping Sphere-Plane Squeeze Flow to Determine the Zero-Shear-Rate viscosity of HDPE Melts
by: Cua Edwin C., et al.
Published: (2004-02-01)

HNMT Upregulation Induces Cancer Stem Cell Formation and Confers Protection against Oxidative Stress through Interaction with HER2 in Non-Small-Cell Lung Cancer
by: Kuang-Tai Kuo, et al.
Published: (2022-01-01)

Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making
by: Evi Abada, et al.
Published: (2023-10-01)

Predictive Value of Epidermal Growth Factor (EGF) andLaminin-5 for Clinicopathologic Oral squamous Cell Carcinoma (OSCC) Staging and Grading in Lranian Population
by: Shima Nafarzadeh, et al.
Published: (2010-11-01)

Ekspresi HER2/neu(c-ErbB2) pada Kanker Kolorektal
by: Nita Afriani, et al.
Published: (2014-12-01)

High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
by: Kåre Nielsen, et al.
Published: (2023-11-01)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
by: Richard L. Schroeder, et al.
Published: (2014-09-01)

Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer
by: Paolo D’Amico, et al.
Published: (2021-12-01)

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
by: Afroditi Nanou, et al.
Published: (2020-08-01)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
by: Cristiano Ferrario, et al.
Published: (2022-04-01)

Identification of Functional Domains in the Cohesin Loader Subunit Scc4 by a Random Insertion/Dominant Negative Screen
by: Michal Shwartz, et al.
Published: (2016-08-01)

Actein Inhibits Tumor Growth and Metastasis in HER2-Positive Breast Tumor Bearing Mice via Suppressing AKT/mTOR and Ras/Raf/MAPK Signaling Pathways
by: Xiao-Xiao Wu, et al.
Published: (2020-05-01)

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
by: Saleh Alrhmoun, et al.
Published: (2022-12-01)

Both Wnt signaling and epidermal stem cell-derived extracellular vesicles are involved in epidermal cell growth
by: Ling Leng, et al.
Published: (2020-09-01)

Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients
by: Ola Abu Al Karsaneh, et al.
Published: (2023-06-01)

Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy
by: Himgauri Naik, et al.
Published: (2021-03-01)

Lack of Association between Selenium Level and Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Tissue
by: Sanaz Salar amoli, et al.
Published: (2019-01-01)

Role of Dendritic Epidermal T Cells in Cutaneous Carcinoma
by: Jian Xiang, et al.
Published: (2020-07-01)

Research on the Construction of Tissue Engineering Epidermal Substitute Based on Collagen-Agarose
by: Yajing ZHAO, et al.
Published: (2021-11-01)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
by: Ibrahim Sadek, et al.
Published: (2017-09-01)

HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration
by: Di Yang, et al.
Published: (2023-10-01)

A stem cell proliferation burst forms new layers of P63 expressing suprabasal cells during zebrafish postembryonic epidermal development
by: Aida Guzman, et al.
Published: (2013-09-01)

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
by: Ran Ran, et al.
Published: (2022-12-01)

Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer
by: Huifang Lv, et al.
Published: (2021-02-01)

Relationship between Calcification on Mammography and Human Epidermal Growth Factor Receptor 2 (HER-2) Expression in Breast Carcinoma
by: Zulfadli Zulfadli, et al.
Published: (2020-06-01)

Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
by: Wei Chen, et al.
Published: (2017-06-01)